Skip to main content

Remedy Mid Tier CVE-2017-17678

MEDIUM
Cross-site Scripting (XSS) (CWE-79)
2021-05-19 cve@mitre.org
6.1
CVSS 3.1 · NVD
Share

Severity by source

NVD PRIMARY
6.1 MEDIUM
AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N

Primary rating from NVD · only source for this CVE.

CVSS VectorNVD

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:L/A:N
Attack Vector
Network
Attack Complexity
Low
Privileges Required
None
User Interaction
Required
Scope
Changed
Confidentiality
Low
Integrity
Low
Availability
None

Lifecycle Timeline

1
CVE Published
May 19, 2021 - 14:15 nvd
MEDIUM 6.1

DescriptionNVD

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility.

AnalysisAI

BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). Rated medium severity (CVSS 6.1), this vulnerability is remotely exploitable, no authentication required, low attack complexity. No vendor patch available.

Technical ContextAI

This vulnerability is classified as Cross-Site Scripting (XSS) (CWE-79), which allows attackers to inject malicious scripts into web pages viewed by other users. BMC Remedy Mid Tier 9.1SP3 is affected by cross-site scripting (XSS). A DOM-based cross-site scripting vulnerability was discovered in a legacy utility. Affected products include: Bmc Remedy Mid-Tier.

RemediationAI

No vendor patch is available at time of analysis. Monitor vendor advisories for updates. Sanitize all user input, use Content-Security-Policy headers, encode output contextually (HTML, JS, URL). Use frameworks with built-in XSS protection.

Share

CVE-2017-17678 vulnerability details – vuln.today

This site uses cookies essential for authentication and security. No tracking or analytics cookies are used. Privacy Policy